Clinical Trials Sponsored by Group Data Management Biostatistics

Total 14 results

Abbott
Group Data Management Biostatistics

Completed

Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis

Austria
Abbott
Assign Data Management and Biostatistics GmbH

Completed

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs (QUALITY)

Psoriasis Chronic

Austria
Abbott
Assign Data Management and Biostatistics GmbH

Completed

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Premature Infants

Austria
Arbeitsgemeinschaft medikamentoese Tumortherapie
Amgen; Assign Data Management and Biostatistics GmbH

Active, not recruiting

Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients (DEFENCE)

Multiple Myeloma

Austria, Germany, Israel
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Optimapharm

Withdrawn

A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract

Gastrointestinal Cancer

Germany
AbbVie (prior sponsor, Abbott)
Assign Data Management and Biostatistics GmbH

Completed

Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years

Secondary Hyperparathyroidism | Chronic Kidney Disease Stage V | Cardiac Morbidity

Austria
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
AIO-Studien-gGmbH
Amgen; Assign Data Management and Biostatistics GmbH; Assign Clinical Research...

Terminated

Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER)

Esophageal Squamous Cell Cancer

Germany
University of Ulm
Sanofi; Assign Data Management and Biostatistics GmbH; Hubertus-Wald-Cancer Center...

Unknown

PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD)

Metastatic Colorectal Cancer

Germany
Themis Bioscience GmbH
Assign Data Management and Biostatistics GmbH; Coalition for Epidemic Preparedness... and other collaborators

Completed

A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)

Lassa Virus Infection

Belgium
Arbeitsgemeinschaft medikamentoese Tumortherapie
Medical University of Vienna; Sanofi; Assign Data Management and Biostatistics... and other collaborators

Recruiting

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Newly Diagnosed Multiple Myeloma

Austria, Greece, Serbia
Trin Therapeutics GmbH
University Hospital, Essen; Assign Data Management and Biostatistics GmbH; Central...

Unknown

Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas

Neoplasms

Germany
Central European Society for Anticancer Drug Research
University Hospital, Essen; University Hospital, Basel, Switzerland; Assign Data... and other collaborators

Completed

Central European Society for Anticancer Research (CESAR) Study of Paclitaxel Therapeutic Drug Monitoring (CEPAC-TDM)

Carcinoma, Non-Small-Cell Lung

Switzerland, Germany
Bioverativ, a Sanofi company
Assign Data Management and Biostatistics GmbH; Quest Diagnostics-Nichols Insitute and other collaborators

Completed

Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders (BIVV009-01)

End-stage Renal Disease (ESRD) | Cold Agglutinin Disease (CAD) | Bullous Pemphigoid (BP) | Warm Autoimmune Hemolytic Anemia (WAIHA)

Austria

Clinical Trials Sponsored by Group Data Management Biostatistics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations